An Evidence-Based Update on Anticholinergic Use for Drug-Induced Movement Disorders Authors (first, second and last of 12) Nora Vanegas-ArroyaveStanley N. CaroffSamantha A. Cicero Content type: Current Opinion Open Access Published: 19 March 2024 Pages: 239 - 254
Treatment of Sleep, Motor and Sensory Symptoms with the Orexin Antagonist Suvorexant in Adults with Idiopathic Restless Legs Syndrome: A Randomized Double-Blind Crossover Proof-of-Concept Study Authors (first, second and last of 7) Diego Garcia-BorregueroAlba Garcia AragónMarÃa Castillo Content type: Original Research Article Published: 21 January 2024 Pages: 45 - 54
Efficacy and Safety of MAO-B Inhibitors Safinamide and Zonisamide in Parkinson’s Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Authors (first, second and last of 9) Laila AboulattaLara HaidarSherif Eltonsy Content type: Systematic Review Published: 16 November 2023 Pages: 941 - 956
Comparative Effectiveness of Device-Aided Therapies on Quality of Life and Off-Time in Advanced Parkinson’s Disease: A Systematic Review and Bayesian Network Meta-analysis Authors (first, second and last of 14) Angelo AntoniniRajesh PahwaK. Ray Chaudhuri Content type: Systematic Review Open Access Published: 21 November 2022 Pages: 1269 - 1283
Cell Biology of Parkin: Clues to the Development of New Therapeutics for Parkinson’s Disease Authors (first, second and last of 4) Jaimin PatelNikhil PanickerTed M. Dawson Content type: Leading Article Published: 15 November 2022 Pages: 1249 - 1267
The XINDI Study: A Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Safinamide as Add-On Therapy to Levodopa in Chinese Patients with Parkinson’s Disease with Motor Fluctuations Authors (first, second and last of 15) Qianqian WeiYuyan Tanthe XINDI Study Investigators Group Content type: Original Research Article Open Access Published: 08 November 2022 Pages: 1217 - 1227
Antiseizure Drugs and Movement Disorders Authors (first, second and last of 6) Michel Sáenz-FarretMarina A. J. TijssenAlfonso Fasano Content type: Review Article Published: 21 July 2022 Pages: 859 - 876
COMT Inhibitors in the Management of Parkinson’s Disease Authors Margherita FabbriJoaquim J. FerreiraOlivier Rascol Content type: Review Article Published: 25 February 2022 Pages: 261 - 282
Slowing Parkinson’s Disease Progression with Vaccination and Other Immunotherapies Authors Dhanya VijayakumarJoseph Jankovic Content type: Leading Article Published: 25 February 2022 Pages: 327 - 343
Amantadine Revisited: A Contender for Initial Treatment in Parkinson’s Disease? Authors (first, second and last of 4) Sarah MarmolMatthew FeldmanJason Margolesky Content type: Current Opinion Published: 14 October 2021 Pages: 1141 - 1152
24-Hour Levodopa-Carbidopa Intestinal Gel: Clinical Experience and Practical Recommendations Authors (first, second and last of 6) Sandeep ThakkarVictor S. C. FungNorbert Kovács Content type: Current Opinion Open Access Published: 13 February 2021 Pages: 137 - 149
Rotigotine Transdermal Patch for Motor and Non-motor Parkinson’s Disease: A Review of 12 Years’ Clinical Experience Authors (first, second and last of 8) Vanessa RaederIro BouraK. Ray Chaudhuri Content type: Review Article Open Access Published: 09 February 2021 Pages: 215 - 231
Opicapone: A Review in Parkinson’s Disease Authors Lesley J. Scott Content type: Adis Drug Evaluation Published: 11 January 2021 Pages: 121 - 131
Evaluation of Prescription Practices of Domperidone in Parkinson’s Disease: A Cross Sectional Study Among French Neurologists Authors (first, second and last of 8) Diane LastennetLouise-Laure MarianiFlorence Tubach Content type: Original Research Article Published: 05 December 2020 Pages: 1267 - 1274
Improving the Delivery of Levodopa in Parkinson’s Disease: A Review of Approved and Emerging Therapies Authors (first, second and last of 4) Daniele UrsoK. Ray ChaudhuriPeter Jenner Content type: Review Article Published: 04 November 2020 Pages: 1149 - 1163
Non-Dopaminergic Treatments for Motor Control in Parkinson’s Disease: An Update Authors (first, second and last of 4) Paulina Gonzalez-LatapiSuvorit Subhas BhowmickSusan H. Fox Content type: Review Article Published: 12 August 2020 Pages: 1025 - 1044
Enhancing the Activity of Glucocerebrosidase as a Treatment for Parkinson Disease Authors Elisa MenozziAnthony H. V. Schapira Content type: Leading Article Published: 01 July 2020 Pages: 915 - 923
β-Adrenoceptor Drugs and Parkinson’s Disease: A Nationwide Nested Case–Control Study Authors (first, second and last of 5) Sibylle de GermayCécile ConteMaryse Lapeyre-Mestre Content type: Original Research Article Published: 04 June 2020 Pages: 763 - 772
Restoring Function to Dopaminergic Neurons: Progress in the Development of Cell-Based Therapies for Parkinson’s Disease Authors Claire HenchcliffeHarini Sarva Content type: Leading Article Published: 29 May 2020 Pages: 559 - 577
Apomorphine for Parkinson’s Disease: Efficacy and Safety of Current and New Formulations Authors (first, second and last of 4) Federico CarboneAtbin DjamshidianWerner Poewe Content type: Review Article Open Access Published: 31 August 2019 Pages: 905 - 918
Novel Treatment Opportunities Against Cognitive Impairment in Parkinson’s Disease with an Emphasis on Diabetes-Related Pathways Authors (first, second and last of 5) Holly GreenPanagiota TsitsiPer Svenningsson Content type: Review Article Open Access Published: 28 January 2019 Pages: 143 - 160